Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
J Altern Complement Med. 2013 Aug;19(8):714-20. doi: 10.1089/acm.2012.0295. Epub 2013 Feb 27.
Some ingestible complementary and alternative medicine (CAM) supplements, including herbal remedies, teas, and vitamins, have biological activities that make them likely to interact poorly with conventional chemotherapeutic treatments. This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together.
A total of 219 patients with ovarian cancer who received care from 1 of 2 participating conventional oncology practices were surveyed about CAM use during and after ovarian cancer treatment.
A total of 200 women reported having chemotherapy to treat their ovarian cancer. Of those, 79 (40%) reported using 1 or more CAM supplements that could be cause for concern when taken with 1 or more of the chemotherapy medications they were receiving. Many patients took multiple supplements of potential concern. Of these women, 42% (n=33) consulted with a conventional provider and 24% (n=19) consulted with a CAM provider about the contraindicated supplements they used.
Although it is not clear that any of these contraindicated combinations of CAM and conventional therapy actually caused adverse outcomes, increased toxicities, or reduced the effectiveness of primary therapies, all these effects are possible given the substances being used in combination. Research is needed to understand the real risk associated with CAM and conventional polypharmacy. If risks associated with CAM use prove substantial, then improved systems to assure that all women get advice regarding supplement use during ovarian cancer treatment will be needed.
一些可食用的补充剂和替代药物(CAM),包括草药、茶和维生素,具有生物活性,可能会与传统的化疗治疗产生不良相互作用。本研究调查了卵巢癌患者,以记录女性使用可食用的 CAM 补充剂和传统化疗药物的程度,这些药物在联合使用时被认为存在潜在风险。
共有 219 名在 2 家参与的常规肿瘤学诊所接受治疗的卵巢癌患者接受了关于卵巢癌治疗期间和之后 CAM 使用情况的调查。
共有 200 名女性报告接受了化疗以治疗其卵巢癌。在这些女性中,有 79 名(40%)报告使用了 1 种或多种可能与她们正在接受的 1 种或多种化疗药物产生相互作用的 CAM 补充剂。许多患者服用了多种有潜在风险的补充剂。在这些女性中,有 42%(n=33)咨询了常规提供者,24%(n=19)咨询了 CAM 提供者有关他们使用的禁忌补充剂。
尽管目前尚不清楚这些 CAM 和传统疗法的禁忌组合是否实际上导致了不良后果、增加了毒性或降低了主要疗法的效果,但鉴于联合使用的物质,所有这些效果都是可能的。需要研究来了解 CAM 与传统联合用药相关的实际风险。如果与 CAM 使用相关的风险被证明是实质性的,那么就需要改进系统,以确保所有女性在接受卵巢癌治疗期间都能得到有关补充剂使用的建议。